Onkológia 2/2024

Profile of atezolizumab in the treatment of lung cancer

Programed cell death-1/programed death ligand-1 (PD-1/PD-L1) blockade represents a daily practice in the treatment for the patients with advanced non-small-cell lung cancer (NSCLC) . Currently, several immunotherapeutics are approved for treatment NSCLC, either anti-PD1/or anti-CTLA-4 agents (cytotoxic T cell lymphocyte antigen 4). Atezolizumab was the first approved antibody that targets the PD-1 ligand (PD-L1) for treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. (1) In these days is it already used after adjuvant chemotherapy for patients with resected early-stage NSCLC and also we have date in neoadjuvant setting. This review focuses on atezolizumab , its registration studies and ongoing trials.

Keywords: non-small cell lung cancer, NSCLC, immune checkpoint inhibitors, ICI, PD-L1, PD-1, atezolizumab, biomarkers